Evonik has entered into a partnership with evitria to provide a ready-to-use transient protein expression kit based on Chinese Hamster Ovary (CHO) cells, helping biopharmaceutical researchers accelerate early-stage biologics development.

Pfizer and Astellas Pharma have received approval from the US Food and Drug Administration (FDA) for PADCEV (enfortumab vedotin-ejfv) in combination with Keytruda (pembrolizumab) or Keytruda

Teva Pharmaceuticals and Polpharma Biologics have entered into a global licensing agreement under which Teva will receive exclusive rights to commercialise both intravenous and subcutaneous formulations

Vertex Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) to expand the use of CASGEVY® (exagamglogene autotemcel) for patients aged two years and older with sickle cell disease

Viva Biotech and Adjutor Group have announced a collaboration aimed at expanding their international business networks and strengthening engagement with global life sciences partners.

Innovent Biologics and Eli Lilly and Company have signed a distribution and promotion agreement for Verzenios® (abemaciclib) in mainland China.

Ionis Pharmaceuticals has signed a licensing agreement with Recordati, granting the company exclusive rights to develop and commercialise the investigational medicine zilganersen for Alexander disease (AxD)

Passage Bio and Remix Therapeutics have entered into a definitive merger agreement in an all-stock transaction that will combine the two biotechnology companies. Following completion of the deal, the merged business

Combotope Therapeutics has entered into a strategic research collaboration with Boehringer Ingelheim to develop next-generation cancer therapies based on tumour-selective antibodies.

Bayer has entered into a drug discovery collaboration with Iambic Therapeutics, a clinical-stage biotechnology company that develops medicines using artificial intelligence. The partnership will focus on the discovery of small-molecule therapies.